Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

News Daily News

FDA Approves Dabigatran for VTE in Children

Shelley Wood

June 22, 2021

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

L.A. McKeown

March 17, 2021

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

Caitlin E. Cox

September 04, 2020

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Todd Neale

August 18, 2017

News Daily News

Interrupting Anticoagulation? New Guidance Aims to Simplify Periprocedural Decision-Making

Todd Neale

January 09, 2017

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

Todd Neale

November 29, 2016

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

July 17, 2014

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

November 26, 2013

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

Advertisement

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

January 2023 News Roundup

LAA Closure Feasible in Patients With Thrombus: Registry

FDA Approves Dabigatran for VTE in Children

Observational Study Supports Continuing Oral Anticoagulation During PCI

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Interrupting Anticoagulation? New Guidance Aims to Simplify Periprocedural Decision-Making

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content